

Breast Reconstruction



Medicaid Medical Coverage Policy

Effective Date: 03/26/2025
Revision Date: 07/25/2024
Review Date: 07/25/2024
Policy Number: HUM-2030-000
Line of Business: Medicaid

Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Appendix](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Description

Breast reconstruction surgery rebuilds a breast's shape following a mastectomy or trauma and may be performed immediately, be delayed or be completed in stages. The surgeon forms a breast mound by using autologous tissue taken from other areas of an individual's body (abdomen, back, buttocks, thighs), placing an artificial implant, or using a tissue expander if necessary, depending on the final desired breast size.

Breast implants are silicone sacs filled with saline (salt water) or silicone gel. The development of scar tissue around a breast implant may necessitate a capsulotomy (surgical opening and release of scar tissue) or capsulectomy (surgical removal of the entire capsule containing the breast implant surrounded by abnormally thick, hardened tissue).

The type of reconstruction recommended (autologous tissue or implants) depends on an individual's age, body composition, general health status, method of planned cancer treatment or other reason for reconstruction.

Breast reconstruction may require multiple surgeries, such as:

- Nipple and areola reconstruction and tattoo pigmentation
- Revision surgery involving the breast and/or donor site
- Surgery on the opposite breast to correct asymmetry

Autologous fat graft, autologous fat transplant (lipoinjection or lipomodeling) via excision lipectomy, suction lipectomy or liposuction involves the removal of adipose tissue (fat) from another area of the body (abdomen, buttocks, thighs, etc.) which is then transferred to the breast(s) during initial reconstructive surgery.

Chest wall reconstruction with flat closure is a reconstructive surgery option for an individual who is not a candidate for or has chosen not to undergo breast reconstruction with autologous tissue or an implant. The procedure may be done at the time of mastectomy or may be delayed and involves the removal and tightening of extra tissue to create a flat chest wall contour.

Oncoplastic surgery refers to integrating tumor removal and immediate breast reconstruction into the initial surgical procedure. Generally, the surgical oncologist removes the tumor, and the plastic surgeon immediately begins reconstruction.

Examples of breast reconstruction techniques (also called flaps) that use **autologous tissue** include, but may not be limited to:

- **Deep circumflex iliac artery (DCIA)/Ruben's free flap**
- **Deep inferior epigastric perforator (DIEP)**
- **Gluteal artery perforator (GAP)**
- **Latissimus dorsi (LD)**
- **Profunda artery perforator (PAP)**
- **Superficial inferior epigastric artery (SIEA)**
- **Thoracodorsal artery perforator (TAP or TDAP)**
- **Transverse gracilis (TUG)**
- **Transverse rectus abdominus muscle (TRAM)**

The [flap description and name](#) are related to the muscles or blood-supplying vessels used and involve surgically removing tissue, typically fat, skin and muscle, from one area of the body and reattaching it to the chest. Pedicled flaps are positioned with the corresponding vascular origin intact while free flaps require microsurgery to connect the tiny blood vessels needed to supply the transplanted tissue.

Other technologies used or being studied for use in conjunction with breast reconstruction procedures include, but may not be limited to:

Intraoperative tissue perfusion assessment methods have been developed to assist surgeons in determining the viability of tissue-transfer circulation during micro, plastic and reconstructive surgery. The suggested benefits involve reducing tissue necrosis (death) and decreasing the need for a second corrective procedure.

- One method, **indocyanine green (ICG) fluorescence angiography**, also referred to as **fluorescent angiography** or **spy angiography**, involves intravenous injection of ICG dye during surgery. The ICG dye binds to proteins in the blood and emits light when stimulated by a low energy laser or near infrared light. The emitted light facilitates visualization of blood flow through the operative tissue, thus

determining perfusion and viability. Examples of US Food & Drug Administration (FDA)-approved imaging devices or systems used to capture fluorescent images for this purpose include, but may not be limited to, Explorer Air II, FloNavi, Fluobeam LM, Infrared 800 with Flow 800 option, Leica FL 800, PDE-Gen3, SPY fluorescent imaging systems (SPY Elite, SPY-PHI) and EleVision IR Platform (including the VS3-Iridium System).

- **Multispectral imaging** involves taking several photographs under many different wavelengths of light in order to ascertain tissue oxygenation measurements for selected tissue regions. The camera determines the approximate values of oxygen saturation (StO_2), relative oxyhemoglobin (HbO_2) and deoxyhemoglobin levels (Hgb) in superficial tissues and displays a two-dimensional color-coded image of tissue oxygenation. The Snapshot_{NIR} is an example of an FDA-approved multispectral imaging device.
- **Near-infrared spectroscopy (NIRS)** technology is being explored to assess circulation or perfusion in tissue samples. While near-infrared light is scattered in human tissue, some structures, such as hemoglobin, absorb it. NIRS technology uses reflected light to determine the ratio of oxyhemoglobin (HbO_2) and deoxyhemoglobin (Hgb) to permit real-time measurement of tissue oxygen saturation (StO_2) within the selected tissue. The T.Ox and its newer modifications the Intra.Ox and Intra.Ox 2.0 are examples of FDA-approved devices that measure tissue oximetry.
- **Visible light spectroscopy (VLS)** uses a sensor with a white LED light to illuminate target tissue and a light detector that captures reflected light. The sensor is connected to a software-based system using a range of reflected light values from visible light wavelengths. The single-use surface sensors are intended to measure percent tissue oxygen saturation (StO_2) on any skin surface to purportedly assist with monitoring skin flap perfusion after microvascular reconstructive procedures. The T-Stat is an example of an FDA-cleared device.

Lymphatic microvascular surgery is proposed in conjunction with reconstructive surgery to prevent the development of lymphedema that may occur following a mastectomy with axillary lymph node dissection. Lymphatic microsurgical preventive healing approach (LYMPHA) procedures include, but may not be limited to, lymphaticovenous anastomosis (LVA), lymphaticovenous bypass (LVB) or lymph node transfer. **(Refer to Coverage Limitations section)**

Coverage Determination

Requests for autologous fat graft, autologous fat transplant (lipoinjection or lipomodeling) via excision lipectomy, suction lipectomy or liposuction as stand-alone procedures (not in conjunction with other breast reconstruction techniques) require review by a medical director.

Humana members may be eligible under the Plan for **breast reconstruction** following, or in conjunction with:

- A medically necessary mastectomy or lumpectomy (regardless of the date of the mastectomy or lumpectomy); **OR**

- A medically necessary prophylactic mastectomy; **OR**
- Trauma (within 12 months postinjury);

AND for surgical procedures including, but may not be limited to:

- Chest wall reconstruction with flat closure; **OR**
- Free or pedicled flap (DIEP, GAP [IGAP, SGAP], LD, PAP, Ruben's, SIEA, TAP, TDAP, TUG, TRAM, or others); **OR**
- Insertion of breast implants; **OR**
- Insertion of tissue expanders; **OR**
- Mastopexy (including prior to a nipple-sparing mastectomy); **OR**
- Nipple reconstruction and repigmentation (tattoo); **OR**
- Reduction mammoplasty only if necessary to preserve nipple viability prior to a nipple-sparing mastectomy (**medical director review required**)

Correction of Breast Asymmetry

Breast reconstruction surgery to correct breast asymmetry is considered cosmetic except for:

- A medically necessary lumpectomy that results in a deformity; **OR**
- A medically necessary mastectomy; **OR**
- Complications with or removal of breast implant(s) following a medically necessary mastectomy; **OR**
- Trauma (within 12 months postinjury)

Further modification related to achieving symmetry is subject to medical necessity and does not include procedures to fill the flap donor site.

Capsulectomy, Capsulotomy, Breast Implant Removal

Humana members may be eligible under the Plan for **capsulectomy, capsulotomy or breast implant removal** when the following criteria are met:

- Breast implants were placed in conjunction with a medically necessary (noncosmetic) surgery;

AND any of the following

- Capsular contracture ([Baker grade](#) III or IV); **OR**
- Extrusion; **OR**
- Rupture of saline filled, silicone gel or alternative breast implant (confirmed by imaging such as magnetic resonance imaging [MRI] or ultrasound); **OR**
- Implant infection refractory to medical management (eg, antibiotics) unless contraindicated;

AND either:

- Infection confirmed by microbiological analysis of peri-implant fluid aspirate; **OR**
- Presence of symptoms such as fever, redness, elevated white blood cell (WBC) count

Breast Implant Associated Anaplastic Large Cell Lymphoma

Note: The following criteria applies **ONLY** to implant removal related to breast implant associated anaplastic large cell lymphoma BIA-ALCL, as total capsulectomy (complete surgical resection) is the only recommended treatment.^{3,22,23,42}

Humana members may be eligible under the Plan for **total capsulectomy with breast implant removal** for the following indications:

- Pathologic confirmation of breast implant associated anaplastic large cell lymphoma BIA-ALCL by cytological evaluation of seroma fluid or mass with Wright Giemsa stained smears and cell block immunohistochemistry/flow cytometry testing for cluster of differentiation (CD30) and anaplastic lymphoma kinase (ALK) markers⁴²; **OR**
- Removal of Allergan BIOCELL textured breast implants and tissue expanders (due to increased risk of breast implant-associated anaplastic large cell lymphoma [BIA-ALCL])

Breast Implant Associated Squamous Cell Carcinoma

Humana members may be eligible under the Plan for **total capsulectomy with breast implant removal** for a confirmed diagnosis of breast implant associated squamous cell carcinoma.

Humana members may be eligible under the Plan for **reinsertion of breast implants** following a medically necessary removal.

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **breast reconstruction, capsulectomy, capsulotomy or breast implant removal** procedures other than those listed above, or for any indications other than those listed above. All other indications are considered not medically necessary.

Humana members may **NOT** be eligible under the Plan for **nipple reconstruction for inverted nipples or breast reconstruction for naturally occurring breast asymmetry** as these are considered cosmetic.

Humana members may **NOT** be eligible under the Plan for **lymphatic microvascular surgery** in conjunction with breast reconstruction to prevent lymphedema. This is considered experimental/investigational as it is not identified as widely used and generally accepted for the proposed use as reported in nationally recognized peer-reviewed medical literature published in the English language.

Autologous fat graft, autologous fat transplant (lipoinjection or lipomodeling) via excision lipectomy, suction lipectomy or liposuction when performed in conjunction with other breast reconstruction techniques is considered integral to the primary procedure and not separately reimbursable.

Intraoperative assessment of tissue perfusion by any technology including, but not limited to, fluorescence angiography, fluorescent angiography, multispectral imaging, near-infrared spectroscopy, oximetry or visible light spectroscopy is considered integral to the primary procedure and not separately reimbursable.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

| CPT® Code(s) | Description | Comments |
|--------------|---|----------|
| 11920 | Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; 6.0 sq cm or less | |
| 11921 | Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; 6.1 to 20.0 sq cm | |
| 11922 | Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation; each additional 20.0 sq cm, or part thereof (List separately in addition to code for primary procedure) | |
| 11970 | Replacement of tissue expander with permanent implant | |

| | | |
|-------|---|--|
| 11971 | Removal of tissue expander without insertion of implant | |
| 13100 | Repair, complex, trunk; 1.1 cm to 2.5 cm | |
| 13101 | Repair, complex, trunk; 2.6 cm to 7.5 cm | |
| 13102 | Repair, complex, trunk; each additional 5 cm or less (List separately in addition to code for primary procedure) | |
| 14000 | Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less | |
| 14001 | Adjacent tissue transfer or rearrangement, trunk; defect 10.1 sq cm to 30.0 sq cm | |
| 14301 | Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm | |
| 14302 | Adjacent tissue transfer or rearrangement, any area; each additional 30.0 sq cm, or part thereof (List separately in addition to code for primary procedure) | |
| 15650 | Transfer, intermediate, of any pedicle flap (eg, abdomen to wrist, Walking tube), any location | |
| 15740 | Flap; island pedicle requiring identification and dissection of an anatomically named axial vessel | |
| 15770 | Graft; derma-fat-fascia | |
| 15771 | Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate | |
| 15772 | Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure) | |
| 15877 | Suction assisted lipectomy; trunk | |
| 19316 | Mastopexy | |
| 19318 | Breast reduction | |
| 19325 | Breast augmentation with implant | |
| 19328 | Removal of intact breast implant | |
| 19330 | Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel) | |
| 19340 | Insertion of breast implant on same day of mastectomy (ie, immediate) | |
| 19342 | Insertion or replacement of breast implant on separate day from mastectomy | |
| 19350 | Nipple/areola reconstruction | |
| 19355 | Correction of inverted nipples | |
| 19357 | Tissue expander placement in breast reconstruction, including subsequent expansion(s) | |

| | | |
|--|---|-----------------|
| 19361 | Breast reconstruction; with latissimus dorsi flap | |
| 19364 | Breast reconstruction; with free flap (eg, fTRAM, DIEP, SIEA, GAP flap) | |
| 19367 | Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap | |
| 19368 | Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap, requiring separate microvascular anastomosis (supercharging) | |
| 19369 | Breast reconstruction; with bipedicled transverse rectus abdominis myocutaneous (TRAM) flap | |
| 19370 | Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy | |
| 19371 | Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents | |
| 19380 | Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction) | |
| 19396 | Preparation of moulage for custom breast implant | |
| 19499 | Unlisted procedure, breast | |
| 76499 | Unlisted diagnostic radiographic procedure | |
| CPT® Category III Code(s) | Description | Comments |
| No code(s) identified | | |
| HCPCS Code(s) | Description | Comments |
| C1789 | Prosthesis, breast (implantable) | |
| C9733 | Nonophthalmic fluorescent vascular angiography | |
| L8600 | Implantable breast prosthesis, silicone or equal | |
| S2066 | Breast reconstruction with gluteal artery perforator (GAP) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral | |
| S2067 | Breast reconstruction of a single breast with "stacked" deep inferior epigastric perforator (DIEP) flap(s) and/or gluteal artery perforator (GAP) flap(s), including harvesting of the flap(s), microvascular transfer, closure of donor site(s) and shaping the flap into a breast, unilateral | |

| | | |
|-------|--|--|
| S2068 | Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral | |
|-------|--|--|

References

1. Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review. Breast reconstruction after mastectomy: a systematic review and meta-analysis. <https://www.ahrq.gov>. Published July 2021. Updated October 2021.
2. American Society of Plastic Surgeons (ASPS). ASPS statement on breast implant associated squamous cell carcinoma (BIA-SCC). <https://www.plasticsurgery.org>. Published September 8, 2022.
3. American Society of Plastic Surgeons (ASPS). BIA-ALCL summary and quick facts. <https://www.plasticsurgery.org>. Published March 21, 2018. Updated February 24, 2020.
4. American Society of Plastic Surgeons (ASPS). Evidence-Based Clinical Practice Guideline. Autologous breast reconstruction with DIEP or pedicled TRAM abdominal flaps. <https://www.plasticsurgery.org>. Published November 2017.
5. American Society of Plastic Surgeons (ASPS). Evidence-Based Clinical Practice Guideline (ARCHIVED). Breast reconstruction with expanders and implants. <https://www.plasticsurgery.org>. Published March 2013.
6. American Society of Plastic Surgeons (ASPS). Guiding Principles. Post-mastectomy fat graft/fat transfer. <https://www.plasticsurgery.org>. Published December 2012. Updated June 2015.
7. American Society of Plastic Surgeons (ASPS). Statement on breast implant specimens and pathology. Published 2016. <https://www.plasticsurgery.org>.
8. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Breast reconstruction following mastectomy (140.2). <https://www.cms.gov>. Published January 1, 1997.
9. ClinicalKey. Schaverien M, Raine C. Breast reconstruction. In: Dixon J and Barber M. *Breast Surgery: A Companion to Specialist Surgical Practice*. 7th ed. Elsevier; 2024:140-155.e2. <https://www.clinicalkey.com>.
10. ECRI Institute. Clinical Evidence Assessment. Lymphatic microsurgical preventive healing approach (LYMPHA) for preventing lymphedema. <https://www.ecri.org>. Published June 16, 2020.

11. ECRI Institute. Clinical Evidence Assessment. Spy Elite system (Stryker) for assessing tissue perfusion during plastic and reconstructive surgery. <https://www.ecri.org>. Published April 11, 2011. Updated April 25, 2022.
12. ECRI Institute. Hotline Response (ARCHIVED). Cosmetic areola micropigmentation after postmastectomy breast reconstruction. <https://www.ecri.org>. Published May 5, 2017.
13. ECRI Institute. Product Brief (ARCHIVED). PDE-Neo (Mitaka USA/Hamamatsu Photonics) versus Spy Elite system (Novadaq Technologies) for visualizing intraoperative blood flow during breast reconstructive surgery. <https://www.ecri.org>. Published February 4, 2015.
14. ECRI Institute. Product Brief (ARCHIVED). T.Ox tissue oximeter (ViOptix, Inc.) for assessing tissue viability in breast reconstruction. <https://www.ecri.org>. Published February 27, 2014. Updated February 28, 2018.
15. ECRI Institute. Product Brief (ARCHIVED). T-Stat VLS tissue oximeter (Spectros Corp.) for monitoring postsurgical tissue viability. <https://www.ecri.org>. Published May 21, 2018.
16. Gutowski K. Current applications and safety of autologous fat grafts: a report of the ASPS Fat Graft Task Force. *Plast Reconstr Surg*. 2009;124:272-280.
17. Hayes, Inc. Evidence Analysis Research Brief. Fluorescence angiography for mastectomy breast flap perfusion. <https://evidence.hayesinc.com>. Published August 2, 2022. Updated May 3, 2023.
18. Hayes, Inc. Health Technology Assessment. Autologous fat grafting for breast reconstruction after breast cancer surgery. <https://evidence.hayesinc.com>. Published October 21, 2020. Updated November 13, 2023.
19. Hayes, Inc. Health Technology Assessment. Microsurgery for primary prevention of breast cancer associated lymphedema. <https://evidence.hayesinc.com>. Published October 15, 2019. Updated November 14, 2022.
20. Hayes, Inc. Health Technology Brief. Superficial inferior epigastric artery (SIEA) flap procedure for postmastectomy breast reconstruction. <https://evidence.hayesinc.com>. Published November 20, 2014. Updated October 12, 2016.
21. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://www.nccn.org>. Published March 11, 2024.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. T-cell lymphomas. <https://www.nccn.org>. Published May 28, 2024.
23. UpToDate, Inc. Breast implant-associated anaplastic large cell lymphoma. <https://www.uptodate.com>. Updated April 2024.

24. UpToDate, Inc. Breast implant infections. <https://www.uptodate.com>. Updated April 2024.
25. UpToDate, Inc. Complications of reconstructive and aesthetic breast surgery. <https://www.uptodate.com>. Updated April 2024.
26. UpToDate, Inc. Implant-based breast reconstruction and augmentation. <https://www.uptodate.com>. Updated April 2024.
27. UpToDate, Inc. Oncoplastic breast surgery. <https://www.uptodate.com>. Updated April 2024.
28. UpToDate, Inc. Options for autologous flap-based breast reconstruction. <https://www.uptodate.com>. Updated April 29, 2024.
29. UpToDate, Inc. Overview of breast reconstruction. <https://www.uptodate.com>. Updated April 2024.
30. UpToDate, Inc. Overview of flaps for soft tissue reconstruction. <https://www.uptodate.com>. Updated April 2024.
31. US Food & Drug Administration (FDA). 510(k) summary: Fluobeam 800. <https://www.fda.gov>. Published May 7, 2014.
32. US Food & Drug Administration (FDA). 510(k) summary: Infrared 800 with flow 800 option. <https://www.fda.gov>. Published March 3, 2010.
33. US Food & Drug Administration (FDA). 510(k) summary: Kent Camera. <https://www.fda.gov>. Published May 5, 2017.
34. US Food & Drug Administration (FDA). 510(k) summary: Leica FL 800. <https://www.fda.gov>. Published May 9, 2008.
35. US Food & Drug Administration (FDA). 510(k) summary: ODISsey Tissue Oximeter (T.Ox). <https://www.fda.gov>. Published July 1, 2014.
36. US Food & Drug Administration (FDA). 510(k) summary: PDE Neo. <https://www.fda.gov>. Published March 27, 2014.
37. US Food & Drug Administration (FDA). 510(k) summary: SPY fluorescent imaging system. <https://www.fda.gov>. Published September 7, 2007.
38. US Food & Drug Administration (FDA). 510(k) summary: SPY PHI open field handheld fluorescence imaging system. <https://www.fda.gov>. Published January 11, 2017.
39. US Food & Drug Administration (FDA). 510(k) summary: T-Stat microvascular tissue oximeter. <https://www.fda.gov>. Published July 28, 2008.

40. US Food & Drug Administration (FDA). 510(k) summary: VS3-IR-MM. <https://www.fda.gov>. Published June 17, 2015.
41. US Food & Drug Administration (FDA). Risks and complications of breast implants. <https://www.fda.gov>. Updated December 15, 2023.
42. US Food & Drug Administration (FDA). Safety Communication (ARCHIVED). The FDA requests Allergan voluntarily recall Natrell BIOCELL textured breast implants and tissue expanders from the market to protect patients. <https://www.fda.gov>. Published July 24, 2019. Updated June 1, 2020.
43. US Food & Drug Administration (FDA). Safety Communication. Update: reports of squamous cell carcinoma (SCC) in the capsule around breast implants. <https://www.fda.gov>. Updated March 22, 2023.

Appendix

Appendix A – Baker Grading Scale⁴¹

| Grade | Breast appearance |
|-----------|--|
| Grade I | Breast is normally soft and appears natural |
| Grade II | Breast is firm but appears normal |
| Grade III | Breast is firm and appears abnormal |
| Grade IV | Breast is hard, painful and appears abnormal |

Appendix B – Autologous Tissue Procedures

| Flap Name | Description |
|---|--|
| Deep circumflex iliac artery (DCIA), also called Ruben's flap | Tissue overlying or just above the iliac crest (hip) along with a DCIA perforator vessel are harvested for use in cases when the abdominal tissue is insufficient due to a previous abdominoplasty or TRAM procedure |
| Deep inferior epigastric perforator (DIEP) | Fat and skin are moved to the chest from the lower abdominal wall with the vessel in the transplanted tissue reconnected to a vessel under the arm to provide blood supply |
| Gluteal artery perforator (GAP) | Tissue is harvested from the buttocks with perforating vessels from either the superior gluteal artery (SGAP) or inferior gluteal artery (IGAP) as the blood supply for the transplanted tissue |
| Latissimus dorsi (LD) | Harvested tissue (skin and muscle) from the back is tunneled through the axilla (underarm) with the blood supplying vessels (the thoracodorsal artery and vein) intact |
| Profunda artery perforator (PAP) | Skin, fat and blood vessels from the back of the upper thigh are transplanted to the chest |
| Superficial inferior epigastric artery (SIEA) | Uses the same abdominal tissue as the DIEP flap but different blood supplying vessels |
| Thoracodorsal artery perforator (TAP or TDAP) | Tissue retrieved from the same anatomical area as the LD flap however, only skin and subcutaneous tissue are harvested, leaving the latissimus dorsi muscle intact |
| Transverse gracilis (TUG) flap | Tissue retrieved from the upper posterior thigh and lower buttock area for individuals with insufficient lower abdominal fat |
| Transverse rectus abdominus muscle (TRAM) | Skin, fat, blood vessels and at least one abdominal muscle are moved from the lower abdomen to the chest area and the tissue volume is often sufficient enough to shape the breast without an implant |

Change Summary

01/01/2025 New Policy.